imatinib koanaa
koanaa healthcare gmbh - imatinib mesylate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - Środki przeciwnowotworowe - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. pacjenci, którzy mają niskie lub bardzo niskie ryzyko nawrotu, nie powinni otrzymywać leczenie uzupełniające. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. za wyjątkiem zdiagnozowanych fazie przewlekłej cml, nie ma kontrolowanych badań, które wykazują efekt kliniczny lub zwiększa przeżywalność przy tych chorobach.
levetiracetam fair-med healthcare 250 mg tabletki powlekane
fair-med healthcare gmbh - levetiracetamum - tabletki powlekane - 250 mg
levetiracetam fair-med healthcare 500 mg tabletki powlekane
fair-med healthcare gmbh - levetiracetamum - tabletki powlekane - 500 mg
levetiracetam fair-med healthcare 750 mg tabletki powlekane
fair-med healthcare gmbh - levetiracetamum - tabletki powlekane - 750 mg
levetiracetam fair-med healthcare 1000 mg tabletki powlekane
fair-med healthcare gmbh - levetiracetamum - tabletki powlekane - 1000 mg
levetiracetam fair-med healthcare 100 mg/ml roztwór doustny
fair-med healthcare gmbh - levetiracetamum - roztwór doustny - 100 mg/ml
levetiracetam fair-med healthcare 100 mg/ml koncentrat do sporządzania roztworu do infuzji
fair-med healthcare gmbh - levetiracetamum - koncentrat do sporządzania roztworu do infuzji - 100 mg/ml
exemestane fair-med. healthcare 25 mg tabletki powlekane
fair-med healthcare gmbh - exemestanum - tabletki powlekane - 25 mg
letrozole fair-med healthcare 2,5 mg tabletki powlekane
fair-med healthcare gmbh - letrozolum - tabletki powlekane - 2,5 mg
telmisartan fair-med 20 mg tabletki
fair-med healthcare gmbh - telmisartanum - tabletki - 20 mg